These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW Diabetes Obes Metab; 2017 Jun; 19(6):831-841. PubMed ID: 28116795 [TBL] [Abstract][Full Text] [Related]
6. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K; Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece. Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695 [TBL] [Abstract][Full Text] [Related]
8. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064 [TBL] [Abstract][Full Text] [Related]
10. Initiation of dapagliflozin and treatment-emergent fractures. Toulis KA; Bilezikian JP; Thomas GN; Hanif W; Kotsa K; Thayakaran R; Keerthy D; Tahrani AA; Nirantharakumar K Diabetes Obes Metab; 2018 Apr; 20(4):1070-1074. PubMed ID: 29193543 [TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. Norhammar A; Bodegård J; Nyström T; Thuresson M; Nathanson D; Eriksson JW Diabetes Obes Metab; 2019 May; 21(5):1136-1145. PubMed ID: 30609272 [TBL] [Abstract][Full Text] [Related]
12. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931 [TBL] [Abstract][Full Text] [Related]
13. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029 [TBL] [Abstract][Full Text] [Related]
15. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study. Seong JM; Kim JJ; Kim HJ; Sohn HS Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319 [TBL] [Abstract][Full Text] [Related]
16. Effect of Dapagliflozin on Ventricular Remodeling and Prognosis in Patients with Coronary Atherosclerotic Heart Disease Undergoing Percutaneous Coronary Intervention. Ye L; Wang K; Sheng H; Shi X; Yan L Altern Ther Health Med; 2024 Apr; 30(4):204-208. PubMed ID: 37944964 [TBL] [Abstract][Full Text] [Related]
17. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Zinman B; Wanner C; Lachin JM; Fitchett D; Bluhmki E; Hantel S; Mattheus M; Devins T; Johansen OE; Woerle HJ; Broedl UC; Inzucchi SE; N Engl J Med; 2015 Nov; 373(22):2117-28. PubMed ID: 26378978 [TBL] [Abstract][Full Text] [Related]
18. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials. Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426 [TBL] [Abstract][Full Text] [Related]
19. Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis. Brown RE; Gupta N; Aronson R Diabetes Technol Ther; 2017 Nov; 19(11):685-691. PubMed ID: 28829163 [TBL] [Abstract][Full Text] [Related]
20. Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers. Idzerda NMA; Stefansson BV; Pena MJ; Sjostrom DC; Wheeler DC; Heerspink HJL Nephrol Dial Transplant; 2020 Sep; 35(9):1570-1576. PubMed ID: 31005993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]